Ferrante M, Feagan BG, Pans J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, DHaens GR (2021) Long-term safety and efficacy of Risankizumab treatment in patients with crohns disease: results from the phase 2 open-label extension study
They can then change the dose if needed
Cardiovascular safety trial demonstrating that the DPP-4 inhibitor alogliptin does not increase MACE in patients with T2DM who had a recent acute coronary event
CJC-1295 and Ipamorelin stimulate the body natural growth hormone release, which enhances tissue repair, muscle recovery, and fat metabolism
Five days after my first injection, I'm off work, drinking Pedialyte, trying to get my strength back, and avoid being hospitalized